查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970930

喉癌治疗市场－全球产业规模、份额、趋势、机会、预测：按产品、最终用户、地区和竞争对手划分，2021-2031年

Laryngeal Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球喉癌治疗市场预计将从 2025 年的 40.9 亿美元成长到 2031 年的 53.6 亿美元，复合年增长率为 4.61%。

此领域涵盖用于治疗喉部恶性肿瘤的药物和生物製药。市场成长的主要驱动因素是全球头颈癌发病率的上升（通常与长期吸烟和饮酒有关）以及标靶免疫疗法的广泛应用。例如，美国癌症协会估计，到2025年，美国将新增约13,020例喉癌。

市场概览
预测期 2027-2031
市场规模：2025年 40.9亿美元
市场规模：2031年 53.6亿美元
复合年增长率：2026-2031年 4.61%
成长最快的细分市场 生物製药
最大的市场 北美洲

然而，新型治疗方法的高昂成本是市场扩张的一大障碍。先进生物製药和免疫查核点抑制剂带来的沉重经济负担限制了患者的药物机会，尤其是在发展中地区。这种经济壁垒构成了一项重大挑战，可能限制这些先进治疗方法的普及，并阻碍其在全球市场的更广泛成长和渗透。

市场驱动因素

全球喉癌发生率的不断上升是推动市场发展的主要因素，这主要归因于吸烟和饮酒等高风险行为。日益加重的患者负担凸显了对有效药物治疗方案的需求，并推动了对传统化疗和新兴生物疗法的需求。国际卫生预测凸显了这一情况的迫切性。例如，国际癌症研究机构（IARC）在2024年2月发布的新闻稿中预测，到2050年，新增癌症病例将激增77%，强调了长期持续供应治疗药物以应对日益增长的疾病负担的必要性。

此外，免疫疗法和标靶治疗的进步显着推动了市场发展，大大改善了转移性或復发性疾病患者的临床疗效。製药公司正大力投资研发，以推出免疫查核点抑制剂，与标准细胞毒性疗法相比，这些抑制剂能够提高病患的存活率。这些先进治疗方法的商业性成功体现在其快速普及应用上。 2024年2月，默克公司报告称，Keytruda的全球销售额在2023年成长了19%，达到250亿美元。患者数量的持续成长进一步支撑了这一成长趋势，美国国家癌症研究所估计，2024年美国将新增12,630例喉癌病例。

市场挑战

新型治疗方法的高昂费用对全球喉癌治疗市场构成重大挑战。先进疗法，尤其是免疫查核点抑制剂和生物目标製剂，其价格远高于传统的放射线治疗和化疗通讯协定。这种价格差异对中低收入国家的患者而言构成了一道难以克服的障碍，因为这些国家的医疗体系往往不足以涵盖这些昂贵的药物。因此，在对成本高度敏感的地区，这些疗法的普及率受到抑制，收入潜力也受到限制。

此外，这些昂贵治疗带来的经济负担迫使许多患者推迟或放弃必要的治疗，实际上缩小了接受治疗的患者群体。根据美国癌症协会预测，到2024年，约60%的适龄癌症倖存者将面临经济困难，例如难以支付医疗费用或因费用问题而延误治疗。这种经济负担极大地限制了进行性喉癌治疗的实际普及程度，使很大一部分目标人口无法获得治疗，并阻碍了治疗市场的整体成长。

市场趋势

新辅助免疫疗法通讯协定的兴起正在重塑全球市场格局，其方法是在局部晚期癌症患者接受手术治疗前引入免疫查核点抑制剂。这种策略旨在降低肿瘤分期并清除微转移灶，与传统的放射线治疗方案相比，可显着延长患者的无无恶化存活期。随着新数据证实新辅助免疫疗法能够在不延迟根治性手术的情况下改善治疗效果，其临床应用正在加速。华盛顿大学医学院2025年4月发布的报告显示，接受Pembrolizumab合併标准疗法治疗的患者，其中位无癌症存活期为51.8个月，而仅接受标准疗法的患者中位无癌症存活期为30.4个月。

同时，针对HPV相关病例，在降低治疗强度方面也取得了进展，旨在减少预后良好患者的治疗相关併发症。肿瘤科医师正利用生物标记筛选适合降低放射线治疗和化疗强度的患者，在维持高治癒率的同时，最大限度地减少吞嚥困难等长期毒性。鑑于目前病毒性恶性肿瘤的发生率远高于烟草相关病例，这种个人化治疗方法显得特别重要。美国疾病管制与预防中心（CDC）在2025年12月报告称，每年将新增约49,908例HPV相关癌症病例，这凸显了此类器官保留治疗方法的市场需求不断增长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：喉癌治疗药物的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（生物製药、小分子化合物）
    • 依最终使用者（医院/诊所、门诊中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美喉癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲喉癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区喉癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲喉癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美喉癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球喉癌治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Johnson & Johnson
  • Cipla Ltd
  • Abbott Laboratories Inc
  • AbbVie Inc
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Lupin Ltd
  • Pfizer Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19044

The Global Laryngeal Cancer Therapeutics Market is projected to expand from USD 4.09 Billion in 2025 to USD 5.36 Billion by 2031, registering a compound annual growth rate of 4.61%. This sector comprises pharmaceutical and biologic interventions developed to treat malignant neoplasms originating in the larynx. The market's growth is primarily fueled by the increasing global incidence of head and neck carcinomas, which are often linked to prolonged tobacco and alcohol use, as well as the rising utilization of targeted immunotherapies. For instance, the American Cancer Society estimated that approximately 13,020 new cases of laryngeal cancer would be diagnosed in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.09 Billion
Market Size 2031USD 5.36 Billion
CAGR 2026-20314.61%
Fastest Growing SegmentBiologics
Largest MarketNorth America

However, market expansion faces a substantial hurdle due to the exorbitant costs associated with novel treatment regimens. The significant financial load imposed by advanced biologic drugs and immune checkpoint inhibitors restricts patient access, particularly in developing regions. This economic barrier limits the reach of these sophisticated treatments and creates a formidable challenge that could inhibit the broader growth and penetration of the global market.

Market Driver

The increasing global prevalence of laryngeal carcinoma acts as a primary catalyst for the market, largely stemming from high-risk behaviors such as tobacco use and alcohol consumption. This rising patient burden necessitates the procurement of effective pharmacological solutions, thereby boosting demand for both traditional chemotherapies and emerging biological treatments. The urgency of this situation is highlighted by international health projections; for example, the International Agency for Research on Cancer predicted in a February 2024 press release that new cancer cases would surge by 77 percent by 2050, emphasizing the long-term need for a sustained therapeutic supply to manage this growing disease load.

Additionally, advancements in immunotherapy and targeted therapeutics are significantly driving the market by transforming clinical outcomes for patients with metastatic or recurrent disease. Pharmaceutical companies are investing heavily in research and development to introduce immune checkpoint inhibitors that improve survival rates compared to standard cytotoxic regimens. The commercial success of these advanced modalities is evident in their rapid adoption; Merck & Co., Inc. reported in February 2024 that global sales of Keytruda increased by 19 percent to 25.0 billion dollars in 2023. This trajectory is further supported by steady patient volumes, with the National Cancer Institute estimating 12,630 new laryngeal cancer diagnoses in the United States in 2024.

Market Challenge

The prohibitive cost of novel treatment regimens presents a major challenge to the Global Laryngeal Cancer Therapeutics Market. Advanced therapies, specifically immune checkpoint inhibitors and targeted biologics, are priced considerably higher than traditional radiation and chemotherapy protocols. This price disparity establishes a significant barrier to entry for patients in low- and middle-income nations, where healthcare reimbursement systems are frequently inadequate to cover these premium pharmaceuticals, consequently suppressing adoption rates and limiting revenue potential in cost-sensitive regions.

Furthermore, the financial toxicity associated with these high-cost regimens forces many patients to delay or forego necessary care, effectively shrinking the active consumer base. According to the American Cancer Society, in 2024, nearly 60% of working-age cancer survivors reported experiencing financial hardship, such as difficulty paying medical bills or delaying treatment due to cost. This economic strain severely restricts the practical reach of advanced laryngeal cancer drugs, rendering them inaccessible to a large segment of the target population and hampering the overall growth trajectory of the therapeutics market.

Market Trends

The rise of Neoadjuvant Immunotherapy Protocols is reshaping the global market by incorporating immune checkpoint inhibitors before surgical intervention for locally advanced disease. This strategic approach aims to downstage tumors and eliminate micrometastases, offering superior event-free survival rates compared to traditional chemoradiation pathways. Clinical adoption is accelerating as new data confirms that perioperative immunotherapy improves outcomes without delaying curative surgeries; according to the Washington University School of Medicine in April 2025, patients treated with pembrolizumab plus standard care achieved a median cancer-free survival of 51.8 months, compared to 30.4 months for those receiving standard care alone.

Simultaneously, the Adoption of Therapeutic De-escalation for HPV-Associated Cases is gaining traction, driven by the goal of reducing treatment-related morbidity in patients with favorable prognoses. Oncologists are increasingly using biomarkers to identify candidates for reduced-intensity radiation and chemotherapy, thereby minimizing long-term toxicities like dysphagia while preserving high cure rates. This personalized approach is vital as virus-driven malignancies rise relative to tobacco-related cases; the Centers for Disease Control and Prevention reported in December 2025 that approximately 49,908 new cancers are detected annually in HPV-associated regions, highlighting the growing market for these refined, organ-preserving regimens.

Key Market Players

  • Johnson & Johnson
  • Cipla Ltd
  • Abbott Laboratories Inc
  • AbbVie Inc
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Lupin Ltd
  • Pfizer Inc

Report Scope

In this report, the Global Laryngeal Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Laryngeal Cancer Therapeutics Market, By Product

  • Biologics
  • Small Molecules

Laryngeal Cancer Therapeutics Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Laryngeal Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Laryngeal Cancer Therapeutics Market.

Available Customizations:

Global Laryngeal Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Laryngeal Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Biologics, Small Molecules)
    • 5.2.2. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Laryngeal Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End-User

7. Europe Laryngeal Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End-User

8. Asia Pacific Laryngeal Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Laryngeal Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End-User

10. South America Laryngeal Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Laryngeal Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cipla Ltd
  • 15.3. Abbott Laboratories Inc
  • 15.4. AbbVie Inc
  • 15.5. Merck KGaA
  • 15.6. Bausch Health Companies Inc.
  • 15.7. Sun Pharmaceutical Industries Ltd
  • 15.8. Aurobindo Pharma Ltd
  • 15.9. Lupin Ltd
  • 15.10. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer